Commentary to the guidelines of the european dermatology forum on the systemic treatment of psoriasis vulgaris;Komentář k Doporučením Evropského dermatologického fóra pro celkovou léčbu psoriasis vulgaris

Cesko-Slovenska Dermatologie

Volumn 85, Issue 4, 2010, Pages 215-218

  Tichy M ^a   Ditrichova D ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Commentary; Guidelines of the Europeran Dermatology Forum for the Systemic Treatment of Psoriasis Vulgaris

Indexed keywords

EID: 77957800240     PISSN: 00090514     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. BENÁKOVÁ, N., CETKOVSKÁ, P., KOJANOVÁ, M. Doporučeni Evropského dermatologického fóra pro celkovou léčbu psoriázy - důležité informace a komentář. Biolo-gická léčba, 2010, 3(1), s. 6-11.
2. BENÁKOVÁ, N., ŠTORK, J. Léčba psoriázy biologiky. Konsensuálni doporučené postupy České dermatovenerolo-gické společnosti ČLS JEP 2006. Čes Slov Derm, 2006, 81(4) Suppl., Sl-11.
3. BENÁKOVÁ, N., ŠTORK, J. Novinky v léčbě psoriázy biologiky a standardními systémovými léky. Čes-slov Derm, 2008, 83(4), s. 191-202.
4. DIXON, WG., HYRICH, KL., WATSON, KD. et al. Drug specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy; results from the BSR biologies register (BSRBR). Rheumatology, 2008, 47, p. 171.
5. GELFAND, JM, TROWEL, AB., LEWIS, JD. et al. The risk of mortality in patients with psoriasis. Arch Dermatol, 2007, 143(12), p. 1493-1499.
6. GIANNETTI, A. Commentary on the European S3- Guidelines on the systemic treatment of Psoriasis. J Eur Acad Dermatol Venereol, 2010, 24, p. 368
7. HERNANDEZ CRUZ, B., CETNER, AS., JORDAN, JE. et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol, 2008,59, p. 363-380.
8. LEONARDI, CL., KIMBALL, AB., PAPP, K. et al. Efficacy and safety of ustekinumab, a human interleukin 12/23 antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371, p. 1665-1674. (Pubitemid 351671883)
9. PATHIRANA, D., ORMEROD, AD., SAIAG, P. et al. European S3- Guidelines on systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol, 2009, 23 Suppl 2., p. 1-70.
10. SMITH, CH., ANSTEY, AV., BARKER, JN. et al. British Association of Dermatologists? guidelines for biologic interventions for psoriasis 2009. Br J Dermatol, 2009, 161(5), p. 987-1019.
11. TICHÝ, M., DITRICHOVÁ, D. Biologika v léč bě těŽkých forem psoriázy. Dermatolog. Praxi, 2007, 1, s. 19-21.
12. TICHÝ, M., DITRICHOVÁ, D. Biologická léčbě v dermatologii. Klin Farmakol Farm, 2008, 22(2), s. 68-71.
13. TYRING, S., GORDON, KB., POULIN, Y. et al. Long-term safety and efficacy of 50mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol, 2007, 143, p. 719-726.
14. van de KERKHOF, PC, SEGAERT, S., LAHFA, M. et al. Once weekly administration of etanercept 50mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomised controlled trial with open-label extension. Br J Dermatol, 2008, 159, p. 1177-1185.